SS-31 vs MOTS-c
Both SS-31 and MOTS-c target mitochondrial function — but through entirely different mechanisms. SS-31 (Elamipretide) directly stabilizes the inner mitochondrial membrane and reduces electron transport chain ROS. MOTS-c activates AMPK to drive metabolic flexibility and mitochondrial biogenesis. This guide breaks down the mechanisms, the evidence, and when to use each.
Cardiac mitochondrial dysfunction, HFpEF-adjacent research, renal ischemia, or when human clinical evidence is a priority.
Insulin resistance, metabolic syndrome, visceral fat, or broad metabolic longevity protocols.
Mechanism Deep Dive
SS-31 (Elamipretide)
Target: Cardiolipin — a phospholipid unique to the inner mitochondrial membrane that anchors the electron transport chain complexes and maintains cristae architecture.
Mechanism: SS-31's alternating aromatic and cationic residues allow it to selectively concentrate in the inner mitochondrial membrane (100-fold over cytoplasm). It binds cardiolipin, stabilizes cristae structure, and prevents cardiolipin peroxidation — the key event that disrupts Complex I/III electron transfer and releases cytochrome c.
Net effect: Restored ATP synthesis, reduced superoxide generation, preserved cristae morphology, and protection against ischemia-reperfusion injury.
Unique advantage: The only peptide with direct cardiolipin-binding mechanism and Phase 2 human RCT data (SPARCL trial in HFpEF).
MOTS-c
Origin: Encoded within the 12S rRNA gene of mitochondrial DNA — one of the first mitochondria-derived peptides (MDPs) discovered to have systemic hormonal effects.
Mechanism: MOTS-c translocates to the nucleus under metabolic stress and activates AMPK (AMP-activated protein kinase). AMPK activation drives: glucose uptake via GLUT4 translocation, fatty acid oxidation, mitochondrial biogenesis via PGC-1α, and inhibition of mTOR (pro-longevity pathway).
Net effect: Improved insulin sensitivity, reduced visceral fat, enhanced fatty acid oxidation, and increased mitochondrial number and efficiency.
Unique advantage: Systemic metabolic effects via AMPK — the same pathway activated by metformin and exercise. Acts as an endogenous "exercise mimetic."
Pathway Summary: Where Each Peptide Acts
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
Pathway Comparison Diagram
SS-31 binds cardiolipin on the mitochondrial inner membrane to reduce ROS and protect membrane integrity; MOTS-c activates AMPK to drive mitochondrial biogenesis — protection vs proliferation.
Head-to-Head Comparison
| Aspect | SS-31 (Elamipretide) | MOTS-c |
|---|---|---|
| Peptide class | Szeto-Schiller tetrapeptide (SS peptide) | Mitochondria-derived peptide (MDP) |
| Amino acid sequence | D-Arg-Dmt-Lys-Phe-NH₂ (4 residues) | 16-residue peptide encoded by 12S rRNA |
| Primary target | Cardiolipin on inner mitochondrial membrane | AMPK → PGC-1α → mitochondrial biogenesis |
| Mechanism of action | Stabilizes cristae structure, reduces ROS at Complex I/III, restores ATP synthesis | Activates AMPK to improve insulin sensitivity, fatty acid oxidation, and mitochondrial turnover |
| Tissue specificity | Highest in cardiac, renal, and skeletal muscle mitochondria | Systemic — skeletal muscle, liver, adipose, heart |
| Human clinical data | Phase 2 RCT (SPARCL): improved exercise capacity in HFpEF; Phase 2 renal ischemia data | No published human RCTs; Phase 1 safety data only |
| Primary research use | Cardiac mitochondrial dysfunction, HFpEF, renal ischemia-reperfusion injury | Insulin resistance, metabolic syndrome, obesity-related metabolic dysfunction |
| Route of administration | IV infusion (clinical trials); subcutaneous (research) | Subcutaneous injection (research) |
| Half-life | ~2 hours (IV); ~4–6 hours (SC) | ~2–4 hours (SC) |
| Cycle length | 4–12 weeks; often used acutely for ischemia | 8–16 weeks with cycling |
| Synergy potential | Pairs with NAD+ precursors, CoQ10, MitoQ | Pairs with SS-31, NAD+, GLP-1 for metabolic protocols |
| Regulatory status | IND-stage (Stealth BioTherapeutics); research chemical | Research chemical; no IND or approved indication |
| Evidence strength | Strongest human data of any mitochondrial peptide | Preclinical + Phase 1 only; human efficacy unproven |
Evidence Summary
SS-31 Evidence
Phase 2 Human RCTsPhase 2 RCT in heart failure with preserved ejection fraction. Elamipretide (SS-31) IV infusion significantly improved 6-minute walk distance and quality of life vs placebo. Primary endpoint met.
Phase 2 data in patients undergoing cardiac surgery with cardiopulmonary bypass. SS-31 reduced acute kidney injury biomarkers vs placebo.
Hundreds of preclinical studies across cardiac, renal, skeletal muscle, and neurological models. Consistent cardiolipin-binding mechanism confirmed across species.
MOTS-c Evidence
Phase 1 + PreclinicalLee et al. (Cell Metabolism, 2015) identified MOTS-c as a mitochondria-derived peptide that regulates insulin sensitivity via AMPK. Foundational paper establishing the MDP concept.
Reynolds et al. (Nature Communications, 2021): MOTS-c levels increase with exercise in humans; exogenous MOTS-c improved exercise capacity in aged mice. Suggests an endogenous exercise-signaling role.
Phase 1 safety data available; well-tolerated at research doses. No published Phase 2 efficacy RCTs in humans as of 2026.
What the cited studies used
One row per compound: the amount and schedule administered in a specific indexed study, who received it, and the paper. These are reports of what was done in that study, not recommendations, and several are animal or single-dose studies. Where no indexed human regimen exists we say so rather than print a number. Community "stacks" and cycle schedules are not reproduced on this site.
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
| Compound | Regimen in the study | Population | Source |
|---|---|---|---|
| SS-31 (elamipretide) | Single 4-hour intravenous infusion at 0.005, 0.05 or 0.25 mg/kg/h A dose-ranging safety study, not a chronic subcutaneous regimen. | Adults with heart failure with reduced ejection fraction (n = 36), randomised, placebo-controlled | PMID 29217757 Daubert et al., Circ Heart Fail 2017 |
| MOTS-c | Intraperitoneal injection in mice (the amount is in the paper's methods, not its abstract; we do not reproduce it) No human interventional trial. Reynolds 2021 (PMID 33473109) adds late-life mouse dosing and human plasma observations after exercise — not administration to people. | Mice — age-related and high-fat-diet insulin resistance models | PMID 25738459 Lee et al., Cell Metab 2015 |
| NAD+ (via nicotinamide riboside) | Nicotinamide riboside 1,000 mg/day oral (500 mg twice daily) for 6 weeks A 2 × 6-week crossover of an oral precursor (the abstract states the design; the 500 mg twice-daily amount is in the methods). We have no PubMed-indexed trial of intravenous NAD+ at the gram amounts sold by clinics. | Healthy middle-aged and older adults (n = 24), randomised crossover | PMID 29599478 Martens et al., Nat Commun 2018 |
Which Should You Research? — Decision Matrix
| Research Goal | Recommended | Rationale |
|---|---|---|
| Cardiac mitochondrial dysfunction / HFpEF-adjacent research | SS-31 | Phase 2 human RCT data (SPARCL); direct cardiolipin stabilization; strongest evidence of any mitochondrial peptide |
| Insulin resistance / metabolic syndrome | MOTS-c | AMPK activation improves insulin sensitivity; direct metabolic mechanism; better evidence for metabolic endpoints |
| Renal ischemia-reperfusion injury | SS-31 | Preclinical and Phase 2 human data for renal protection; no MOTS-c data for this indication |
| Visceral fat / obesity-related metabolic dysfunction | MOTS-c | AMPK-driven fatty acid oxidation; pairs well with GLP-1 and Tesamorelin for metabolic protocols |
| Exercise capacity / skeletal muscle mitochondria | Toss-up | SS-31 has human exercise capacity data (HFpEF); MOTS-c has preclinical data for exercise mimetic effects. Stack both for comprehensive coverage. |
| Longevity / anti-aging (broad) | Stack both | Complementary mechanisms — SS-31 for membrane integrity and ROS reduction; MOTS-c for biogenesis and metabolic flexibility. No head-to-head longevity data. |
| Neurodegeneration / cognitive protection | SS-31 (slight edge) | SS-31 has preclinical data in Alzheimer's models; MOTS-c has limited CNS data. Neither has human cognitive trial data. |
| Budget-constrained single compound | MOTS-c | Lower cost per cycle; broader metabolic applicability; easier to source as research chemical |
Frequently Asked Questions
What is the difference between SS-31 and MOTS-c?
SS-31 (Elamipretide) is a synthetic tetrapeptide that directly targets cardiolipin on the inner mitochondrial membrane, stabilizing cristae structure and reducing reactive oxygen species at the electron transport chain. MOTS-c is a naturally occurring mitochondria-derived peptide that activates AMPK to improve insulin sensitivity, fatty acid oxidation, and mitochondrial biogenesis. SS-31 works at the level of mitochondrial membrane integrity; MOTS-c works at the level of metabolic signaling and mitochondrial turnover.
Which has stronger human clinical evidence — SS-31 or MOTS-c?
SS-31 (Elamipretide) has significantly stronger human clinical evidence. It has completed Phase 2 randomized controlled trials including the SPARCL trial in heart failure with preserved ejection fraction (HFpEF), demonstrating improved exercise capacity, and Phase 2 trials in renal ischemia-reperfusion injury. MOTS-c has only Phase 1 safety data in humans; no published human efficacy RCTs exist as of 2026.
Can SS-31 and MOTS-c be stacked together?
Yes — SS-31 and MOTS-c have complementary, non-overlapping mechanisms that make them a logical stack for comprehensive mitochondrial optimization. SS-31 addresses mitochondrial quality (membrane integrity, ROS reduction, cristae stabilization) while MOTS-c addresses mitochondrial quantity and metabolic efficiency (AMPK-driven biogenesis, insulin sensitization, fatty acid oxidation). No human stacking data exists, but the mechanistic rationale is well-supported by preclinical research.
What is SS-31 used for in research?
SS-31 (Elamipretide) is primarily researched for cardiac mitochondrial dysfunction — particularly heart failure with preserved ejection fraction (HFpEF), where mitochondrial cristae disruption and reduced ATP synthesis are central to the pathophysiology. It is also studied for renal ischemia-reperfusion injury, skeletal muscle mitochondrial dysfunction, and age-related mitochondrial decline. Its unique mechanism — direct cardiolipin binding — makes it the most mechanistically specific mitochondrial peptide in the research pipeline.
What is MOTS-c used for in research?
MOTS-c is primarily researched for metabolic disorders — insulin resistance, type 2 diabetes, obesity, and metabolic syndrome. Its mechanism involves activating AMPK, which improves insulin sensitivity, promotes fatty acid oxidation, and drives mitochondrial biogenesis. It is also studied as an 'exercise mimetic' — preclinical data suggests MOTS-c can replicate some metabolic benefits of exercise at the cellular level. Longevity research is an emerging area given its mitochondrial-derived origin.
Is SS-31 the same as Elamipretide?
Yes. SS-31 is the research name for Elamipretide, the IND-stage compound developed by Stealth BioTherapeutics (now Stealth Peptides). The 'SS' designation refers to the Szeto-Schiller peptide series. In research settings, it is commonly referred to as SS-31; in clinical trial literature, it appears as Elamipretide or MTP-131.
How do SS-31 and MOTS-c differ from NAD+ precursors?
NAD+ precursors (NMN, NR) work by replenishing the NAD+/NADH ratio, which is required for the electron transport chain and sirtuin activity. SS-31 works upstream of NAD+ — it stabilizes the mitochondrial membrane architecture that allows the electron transport chain to function efficiently. MOTS-c works through AMPK, which is a parallel pathway to sirtuins (SIRT1). All three are complementary: NAD+ provides the substrate, SS-31 ensures the machinery works, and MOTS-c drives biogenesis of new mitochondria.
What are the side effects of SS-31 and MOTS-c?
SS-31 (Elamipretide) has been well-tolerated in Phase 2 clinical trials. The most commonly reported adverse events are injection site reactions (mild erythema, bruising) and transient fatigue. No serious adverse events attributable to SS-31 were reported in the SPARCL trial. MOTS-c has limited human safety data. Preclinical studies show a favorable safety profile; the most commonly reported effects in research use are mild injection site reactions and transient hypoglycemia at higher doses in insulin-sensitive individuals.